Adults aged 18-59 years (inclusive) with an at least 6-month history of papulopustular rosacea (PPR) are needed for a clinical trial. Eligible participants must have moderate to severe PPR and have 20 to 70 inflammatory lesions (papules and/or pustules) and no more than 2 nodules on the face. In addition, moderate or severe persistent erythema associated with PPR is also required for the study.
Participants will receive investigational topical treatment (active study drug) or placebo. Study treatment and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last approximately 22 weeks and involve about 6 visits to the study centre.
The following information is from ClinicalTrials.gov
Last Update Posted: February 22, 2023
Condition or Disease:
Ages Eligible for Study:
18 to 59
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.
Waterloo - K. Papp Clinical Research
Peterborough - SKiN Centre for Dermatology
Oakville - The Centre for Clinical Trials